System and method to identify vocs from human breath for disease screening and diagnostics
Patent Information
- Application Number
- PCT/IB2026/000302
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-04-01
- Filing Date
- 2026-03-31
- Publication Date
- 2026-11-19
AI Technical Summary
Existing breath analysis devices face challenges in accurately detecting and quantifying volatile organic compound biomarkers due to environmental variability, sample contamination, and lack of advanced sample collection and AI-driven processing, limiting their use in real-time disease screening and diagnostics.
A digital olfaction-based breath analysis device with an aroma chip using composite thin-film sensing elements and conducting nanoparticles, integrated with controlled sample collection pathways and conditioning modules, and AI-driven processing to analyze impedance changes for precise detection and quantification of VOC biomarkers.
Enables reliable, real-time disease screening and diagnostics by overcoming environmental interference and ensuring accurate detection and quantification of VOC biomarkers, suitable for diverse clinical and non-clinical settings.
Smart Images

Figure IB2026000302_19112026_PF_FP_ABST
Abstract
Description
Atty Docket: STR-028W001SYSTEM AND METHOD TO IDENTIFY VOCS FROM HUMAN BREATH FOR DISEASE SCREENING AND DIAGNOSTICSFIELD OF TECHNOLOGY
[0001] The present disclosure relates generally to breath analysis devices, and more specifically to a system to identify volatile organic compound biomarkers for disease detection and diagnosis.BACKGROUND
[0002] Breath analysis is a non-invasive diagnostic approach that may be used to detect health conditions by identifying chemical biomarkers present in exhaled breath. Volatile Organic Compounds (VOCs), along with other chemical constituents, may serve as indicators of specific diseases. Analytical techniques such as gas chromatography-mass spectrometry may be employed to identify these biomarkers with high accuracy. Portable devices for breath analysis may also utilize sensor-based systems to detect and quantify chemical components in breath samples.SUMMARY
[0003] The described techniques relate to improved methods, systems, devices, and apparatuses that support techniques for system to identify volatile organic compound biomarkers for disease detection and diagnosis. Some implementations may provide a digital olfaction-based breath analysis device designed to overcome one or more of the limitations of existing systems. The device may feature an aroma chip comprising composite thin-film sensing elements functionalized with polymers and conducting nanoparticles. These sensing elements may interact with volatile organic compound biomarkers in exhaled breath samples, generating electrical responses that may be transduced into impedance changes. The unique combination of polymers and conducting nanoparticles may ensure high selectivity and sensitivity to a wide range of volatile organic compound biomarkers, enabling precise detection and quantification.
[0004] The device may incorporate controlled sample collection pathways, including a mouthpiece, buffer chamber, and aroma chip enclosure, equipped with valves and sensors such as carbon dioxide sensors and flow sensors. These components may segregate relevant portions of exhaled breath, ensuring optimal sample introduction to the aroma chip. Conditioning1 #19302804vlAtty Docket: STR-028W001modules may be integrated to filter humidity, modulate temperature, and / or remove environmental confounding factors, allowing the device to operate effectively in diverse conditions.
[0005] Artificial intelligence-driven processing may further enhance the device’s capabilities in some embodiments. A processor programmed to execute one or more machine learning models may analyze the transduced impedance changes to identify and quantify volatile organic compound biomarkers. The model(s) may be trained to detect disease-specific breathprints, enabling the device to perform both screening and diagnostic functions. This robust, scalable solution may address one or more of the challenges of environmental variability, sample contamination, and real-time analysis, making it suitable for widespread use in healthcare settings.
[0006] A digital olfaction-based breath analysis device is described. The device may include an aroma chip including composite thin-film sensing elements, each functionalized with a polymer and conducting nanoparticles. The device may include a sample collection pathway including a mouthpiece, a buffer chamber, and valves configured to control the introduction of exhaled breath samples to the aroma chip. The device may include a plurality of conditioning modules configured to modulate environmental factors affecting the aroma chip, including, but not limited to, humidity and / or temperature. The device may include a processor configured to analyze electrical responses from the aroma chip in response to exhaled breath samples. The device may include a communication module configured to transmit data between the processor and a remote server.
[0007] A method of forming a digital olfaction-based breath analysis device is described. The method may include providing an aroma chip with composite thin-film sensing elements, each functionalized with a polymer and conducting nanoparticles. The method may include assembling a sample collection pathway that may include a mouthpiece, a buffer chamber, and valves configured to control the introduction of exhaled breath samples to the aroma chip. The method may include integrating a plurality of conditioning modules configured to modulate environmental factors affecting the aroma chip, including, but not limited to, humidity and / or temperature. The method may include incorporating a processor configured to analyze electrical responses from the aroma chip in response to exhaled breath samples. The method may include installing a communication module configured to transmit data between the processor and a remote server.2 #19302804vlAtty Docket: STR-028W001
[0008] Some examples of the technologies and related methods described herein may further include a conditioning module positioned within the buffer chamber. The conditioning module may be configured to selectively capture exhaled breath condensate and release the condensate to the aroma chip in response to temperature modulation.
[0009] In some examples of the technologies and related methods described herein, the valves of the sample collection pathway may include a valve between the mouthpiece and the buffer chamber. The valve may be configured to segregate relevant portions of exhaled breath samples based on input from a carbon dioxide (CO2) sensor.
[0010] Some examples of the technologies and related methods described herein may further include an exhaled breath capturing module located adjacent to the mouthpiece. The exhaled breath capturing module may be configured to condition exhaled breath samples by filtering humidity prior to introduction into the buffer chamber.
[0011] In some examples of the technologies and related methods described herein, the aroma chip may include sensing elements functionalized with polymers selected for semiselective interaction with functional groups of volatile organic compounds in exhaled breath samples.
[0012] Some examples of the technologies and related methods described herein may further include a conditioning module positioned near the aroma chip. The conditioning module may be configured to modulate the temperature of environment air introduced during baseline and recovery phases.
[0013] In some examples of the technologies and related methods described herein, the buffer chamber may include a configurable volume that is adjustable (e.g., between 150 cc and 500 cc), which may be selected based on the disease condition targeted by the device.
[0014] In some examples of the technologies and related methods described herein, the aroma chip may include sensing elements functionalized with polymers selected to interact with volatile organic compounds dissolved in exhaled breath condensate.
[0015] In some examples of the technologies and related methods described herein, the conditioning module may include a humidity filter comprising desiccant material and filtering media configured to remove water content from exhaled breath samples.3 #19302804vlAtty Docket: STR-028W001
[0016] In some examples of the technologies and related methods described herein, the exhaled breath capturing module may include a bacterial viral filter configured to prevent introduction of bacteria or viruses into the buffer chamber.
[0017] In some examples of the technologies and related methods described herein, the aroma chip may include sensing elements functionalized with polymers selected to produce unique electrical responses based on the presence and concentration of volatile organic compounds.
[0018] Some examples of the technologies and related methods described herein may further include a conditioning module that includes a temperature control module. The temperature control module may be configured to modulate the temperature of exhaled breath samples prior to introduction into the buffer chamber.
[0019] In some examples of the technologies and related methods described herein, the environment air introduced during the baseline phase may be conditioned by the conditioning module to remove humidity prior to interaction with the aroma chip.
[0020] A method for a system to identify volatile organic compound biomarkers for disease detection and diagnosis is described. The method may include receiving exhaled breath sample data from a breath analysis device, the data including transduced impedance values generated by a plurality of sensing elements of an aroma chip. The method may include analyzing the transduced impedance values in response to receiving the exhaled breath sample data to identify patterns indicative of volatile organic compound biomarkers. The method may include comparing the identified patterns with stored reference data associated with volatile organic compound biomarkers to determine the presence and concentration of the biomarkers. The method may include associating the determined biomarkers with stored disease profiles to identify potential health conditions. The method may include recording the associated health conditions and determined biomarkers in a database.
[0021] A system configured for identifying volatile organic compound biomarkers for disease detection and diagnosis may be described. The system may include a processor and memory coupled with the processor. The system may include instructions stored in the memory and executable by the processor to cause the system to receive exhaled breath sample data from a breath analysis device, where the data may include transduced impedance values generated by a plurality of sensing elements of an aroma chip. The system may analyze the transduced impedance values in response to receiving the exhaled breath sample data to identify patterns 4 #19302804vlAtty Docket: STR-028W001indicative of volatile organic compound biomarkers. The system may compare the identified patterns with stored reference data associated with volatile organic compound biomarkers to determine the presence and concentration of the biomarkers. The system may associate the determined biomarkers with stored disease profiles to identify potential health conditions. The system may record the associated health conditions and determined biomarkers in a database.BRIEF DESCRIPTION OF THE DRAWINGS
[0022] FIG. 1 shows device diagram which supports techniques for a system to identify volatile organic compound biomarkers for disease detection and diagnosis in accordance with various aspects of the present disclosure.
[0023] FIG. 2 shows a block diagram of an apparatus that supports a system to identify volatile organic compound biomarkers for disease detection and diagnosis in accordance with various aspects of the present disclosure.
[0024] FIG. 3 shows a block diagram of a breath analysis component that supports a system to identify volatile organic compound biomarkers for disease detection and diagnosis in accordance with various aspects of the present disclosure.
[0025] FIG. 4 shows a diagram of a system including a device that supports a system to identify volatile organic compound biomarkers for disease detection and diagnosis in accordance with various aspects of the present disclosure.
[0026] FIGS. 5 and 6 show flowcharts illustrating methods that support a system to identify volatile organic compound biomarkers for disease detection and diagnosis in accordance with various aspects of the present disclosure.
[0027] FIG. 7 illustrates a schematic view of a breath analysis device according to an embodiment of the present inventionDETAILED DESCRIPTION
[0028] Devices, apparatuses, systems, and methods that support techniques for a system to identify volatile organic compound biomarkers for disease detection and diagnosis are disclosed. In some examples, existing breath analysis devices may face significant challenges in accurately detecting and quantifying volatile organic compound biomarkers under varying environmental conditions. For example, high humidity, temperature fluctuations, and the presence of background contaminants may interfere with the precision of chemical analysis5 #19302804vlAtty Docket: STR-028W001systems. Additionally, some current devices may lack advanced mechanisms for controlled sample collection, leading to loss or contamination of critical biomarkers during the process. The absence of robust conditioning modules may further exacerbate the issue, as environmental factors may compromise the reliability of results. Moreover, the limited integration of artificial intelligence-driven processing may restrict the ability of some existing systems to analyze complex breathprints and correlate them with specific disease conditions. These limitations may hinder the widespread adoption of breath analysis devices for real-time disease screening and diagnostics, necessitating the development of a more advanced solution.
[0029] In some implementations, breath analysis devices may employ digital olfaction technology to detect and measure chemical compounds present in human exhaled breath samples. These devices may analyze the breath sample to determine its chemical composition, which may include volatile organic compounds, non-volatile organic compounds, inorganic compounds, water vapor, aerosols, and liquid droplets. By identifying and quantifying specific chemical compounds, the devices may assess the health condition of the individual providing the sample. This analysis may be particularly useful for detecting chemical markers associated with diseases, enabling the device to serve as a non-invasive diagnostic tool. The ability to analyze breath samples in this manner may provide a convenient and efficient method for health screening and disease diagnosis.
[0030] In some implementations, the devices may include an aroma chip that functions as a sensor for detecting chemical compounds in the breath sample. The aroma chip include multiple sensing elements made from thin films that combine polymers with conducting nanoparticles. Each sensing element may be functionalized with a unique polymer to interact with specific chemical compounds of interest. Alternatively, the sensing elements may use the same polymer but may be functionalized differently by incorporating distinct materials. When the sensing elements interact with the chemical compounds in the breath sample, the thin films may expand or contract, altering the distance between the conducting nanoparticles. This change may result in variations in electrical properties, such as impedance, voltage, or current, across electrodes embedded in the thin films. These variations may be analyzed to generate a fingerprint or “breathprinf ’ unique to the sample, which may reflect the chemical composition of the breath.
[0031] In some implementations, a processor equipped with artificial intelligence and machine learning models may be configured to analyze the electrical variations generated by6 #19302804vlAtty Docket: STR-028W001the aroma chip. These models may be trained to correlate changes in electrical properties with the presence and concentration of specific chemical compounds. The processor may host multiple models, each designed to detect and measure particular sets of chemical compounds associated with different diseases. These models may work collaboratively as an expert system to screen and diagnose diseases based on the breath sample. The processor may be located on a remote server, with the device exchanging data through a communication module, or it may be hosted locally on the device, with processing tasks distributed between the onboard processor and the remote server. This configuration may allow for flexible and efficient data analysis, regardless of the device’s operating environment.
[0032] In some implementations, the device may include a sample collection pathway designed to introduce breath samples to the aroma chip in a controlled manner. This pathway may consist of a mouthpiece, a buffer chamber, and an aroma chip enclosure, with valves placed between these components to regulate the flow of breath samples. The mouthpiece may transfer the breath sample from the individual to the buffer chamber, while a valve may ensure that only relevant portions of the breath sample are introduced into the buffer chamber. The buffer chamber may store the breath sample and release it to the aroma chip in a controlled manner, with its volume adjustable within a preferred range of 150 to 500 cubic centimeters. Another valve may control the introduction of the breath sample from the buffer chamber to the aroma chip enclosure, which may house the aroma chip and provide a space for the sensing elements to interact with the sample. A pump may be included in the aroma chip enclosure to draw the breath sample from the buffer chamber, ensuring precise delivery for analysis.
[0033] In some implementations, sensors may be positioned near the mouthpiece to segregate relevant portions of the breath sample. For example, a carbon dioxide sensor may detect the alveolar portion of the breath, which may contain chemical compounds most relevant for disease screening and diagnosis. A flow sensor may also be used to identify the portion of the breath sample of interest. Based on input from these sensors, a controller may actuate the valve between the mouthpiece and the buffer chamber, ensuring that only the relevant portion of the breath sample is introduced into the buffer chamber. Non-relevant portions of the breath sample may be routed out of the device without entering the buffer chamber, optimizing the analysis process and reducing contamination risks.
[0034] In some implementations, conditioning modules may be included to ensure reliable operation under varying environmental conditions, such as different levels of humidity and7 #19302804vlAtty Docket: STR-028W001temperature. A first conditioning module may be placed before the buffer chamber to condition the exhaled breath sample, potentially using a humidity filter to remove water vapor. A second conditioning module may be positioned near the valve between the aroma chip enclosure and the buffer chamber to condition the environment air introduced to the aroma chip during baseline and recovery phases. These conditioning modules may include materials such as desiccants, filtering media, and / or membranes to absorb and remove humidity. In some cases, the conditioning modules may also include temperature control systems to selectively capture and release exhaled breath condensate. By lowering the temperature, the system may trap condensate, and by raising the temperature, it may release the trapped condensate or chemical compounds dissolved in it. The placement of these modules may vary, with options including the mouthpiece, buffer chamber, or aroma chip enclosure.
[0035] In some implementations, the device may operate in three main phases: baseline, exposure, and recovery. During the baseline phase, the device may analyze the chemical composition of the operating environment to establish a reference point, with environment air introduced to the aroma chip. During the exposure phase, the breath sample may be introduced to the aroma chip for analysis. During the recovery phase, the device may release the breath sample back to the operating environment and prepare for the next sample collection. The workflow may include a purge step to remove the contents of the buffer chamber, ensuring the device is ready for subsequent use. This phased operation may enhance the accuracy and reliability of the analysis by accounting for environmental factors and ensuring proper sample handling.
[0036] In some implementations, the device may be designed to function in diverse environmental conditions, including high and low humidity levels and varying temperatures. For example, the device may be configured to operate in absolute humidity ranges between 1.9 grams per cubic meter and 43 grams per cubic meter and temperatures up to 45 degrees Celsius, with a preferred range of 30 to 40 degrees Celsius. Conditioning modules may play a critical role in minimizing the impact of environmental factors on the analysis of breath samples, ensuring consistent performance across different settings. This adaptability may make the device suitable for use in a wide range of clinical and non-clinical environments.
[0037] In some implementations, the device may screen and diagnose individuals for specific diseases by detecting and measuring chemical compounds in the breath sample. Screening may involve identifying individuals likely to have a disease based on the detected8 #19302804vlAtty Docket: STR-028W001chemical compounds, while diagnosis may determine whether an individual has a disease based on the measured concentration of these compounds. Different sets of chemical compounds may be detected for screening and diagnostic purposes, with varying concentrations used for each application. This capability may enable the device to provide tailored health insights for individual users.
[0038] In some implementations, the device may generate a fingerprint or breathprint for each breath sample based on the electrical variations produced by the sensing elements during interaction with chemical compounds. Each disease may be associated with a specific combination of chemical compounds, which may differ in terms of presence or concentration, resulting in a distinct fingerprint. This approach may allow for precise identification of diseases and may support the development of personalized diagnostic tools.
[0039] In some implementations, hygiene features may be incorporated to ensure safe and sanitary operation. For example, the conditioning module may be placed inside the mouthpiece, making it specific to one person and single-use for an entire breath sample collection session. The conditioning module may include a bacterial and / or viral filter to prevent the introduction of bacteria and / or viruses into the sample collection pathway. These features may enhance the safety and reliability of the device, particularly in settings where multiple users may interact with the same system.
[0040] In some implementations, valves may regulate the flow of breath samples based on the phase of operation and / or the detection of relevant portions of the sample. During the baseline phase, the valve may allow environment air to enter the aroma chip. During the exposure phase, the valve may control the introduction of the breath sample to the aroma chip. During the recovery phase, the valve may allow environment air to enter the aroma chip for recovery. The timing of valve operation may be carefully controlled to minimize the loss of chemical compounds during sample collection and analysis, ensuring accurate and reliable results.
[0041] Aspects of the subject matter described in this disclosure can be implemented to realize one or more of the following potential advantages. The described techniques may be implemented to support non-invasive health monitoring by leveraging breath sample analysis to detect chemical compounds indicative of disease conditions. The device may provide rapid results by processing breath samples in real-time, which may enhance the efficiency of health screening and diagnostic workflows. The modular design of the device may allow for9 #19302804vlAtty Docket: STR-028W001customization to target specific biomarkers associated with various diseases, which may improve diagnostic accuracy. The integration of sensors and conditioning modules may ensure reliable operation in diverse environments, which may make the device suitable for use in both clinical and non-clinical settings. The use of machine learning models may enable adaptive analysis of breath samples, which may facilitate the detection of emerging health conditions or variations in biomarkers.
[0042] Aspects of the disclosure are initially described in the context of breath analysis devices. Aspects of the disclosure are additionally illustrated by and described with reference to example implementations. Aspects of the disclosure are further illustrated by and described with reference to a flowchart that relates to methods involving system to identify volatile organic compound biomarkers for disease detection and diagnosis.
[0043] FIG. 1 shows device diagram 100 which supports techniques for a system to identify volatile organic compound biomarkers for disease detection and diagnosis in accordance with various aspects of the present disclosure. As depicted in FIG. 1, the device diagram 100 may include one or more of an exhaled breath capturing module / buffer chamber 102, a first conditioning module 104, a second conditioning module 106, an aroma chip 108, a multi-way valve 110 and / or other components.
[0044] The exhaled breath capturing module / buffer chamber 102 may include a configurable volume to hold and release breath samples in a controlled manner. The buffer chamber may be designed to accommodate breath samples ranging, for example, from 150 cc to 500 cc, depending on the requirements of the disease condition being analyzed. The buffer chamber may include a valve that controls the introduction of breath samples to the aroma chip 108, ensuring precise sample delivery. In some implementations, the buffer chamber may interact with sensors, such as a CO2 sensor or a flow sensor, to segregate relevant portions of the breath sample for analysis. The buffer chamber may be used in conjunction with the first conditioning module 104 to modulate the humidity of the breath sample before it reaches the aroma chip 108.
[0045] The first conditioning module 104 may include a humidity filter to remove water content from exhaled breath samples before they reach the buffer chamber. The first conditioning module 104 may include desiccant material and / or filtering media to absorb and remove humidity from the breath sample. The first conditioning module 104 may be placed near the mouthpiece of the sample collection pathway to condition the sample before it enters10 #19302804vlAtty Docket: STR-028W001the buffer chamber. In some implementations, the first conditioning module 104 may include a temperature control module to trap exhaled breath condensate and selectively release it into the buffer chamber. The first conditioning module 104 may work in conjunction with the exhaled breath capturing module / buffer chamber 102 to ensure the sample is appropriately conditioned for analysis.
[0046] The second conditioning module 106 may include a humidity filter to remove water content from environment air introduced during baseline and recovery phases. The second conditioning module 106 may include diffusion layers, particulate filters, and / or desiccant material to absorb and remove humidity from the environment air. The second conditioning module 106 may be placed near the valve between the buffer chamber and the aroma chip enclosure to condition the environment air before it reaches the aroma chip 108. In some implementations, the second conditioning module 106 may include submodules, where one submodule filters humidity and another submodule controls the temperature of the environment air. The second conditioning module 106 may interact with the aroma chip enclosure to ensure the environment air is appropriately conditioned during baseline and recovery phases.
[0047] The aroma chip 108 may include a plurality of sensing elements made from composite thin films to detect volatile organic compound biomarkers. The sensing elements of the aroma chip 108 may be functionalized with polymers and conducting nanoparticles to interact with VOC biomarkers. The composite thin films may expand or contract during interaction with VOC biomarkers, altering the electrical impedance across interdigitated electrodes embedded in the films. In some implementations, the aroma chip 108 may generate a unique fingerprint or breathprint based on the combination of impedance changes from the sensing elements. The aroma chip 108 may work in conjunction with a processor to analyze electrical responses and determine the presence and concentration of VOC biomarkers in the breath sample.
[0048] In some implementations, the exhaled breath capturing module / buffer chamber 102 may be positioned to receive the breath sample directly from the mouthpiece, allowing the sample to pass through the first conditioning module 104 before entering the buffer chamber. The first conditioning module 104 may be configured to adjust the temperature of the exhaled breath sample, capturing exhaled breath condensate or VOC biomarkers dissolved in the condensate. The second conditioning module 106 may be situated near the valve connecting11 #19302804vlAtty Docket: STR-028W001the buffer chamber 102 to the aroma chip 108 and may regulate the temperature and humidity of the environment air entering the aroma chip enclosure.
[0049] In some implementations, the aroma chip 108 may be enclosed within a dedicated chamber that interacts with the conditioned breath sample released from the buffer chamber 102. The second conditioning module 106 may include submodules that filter humidity or specific VOCs from the environment air and control the temperature of the air entering the aroma chip 108. The placement of the second conditioning module 106 may allow for precise modulation of environmental factors, ensuring the sample introduced to the aroma chip 108 is conditioned appropriately for interaction with its sensing elements.
[0050] FIG. 2 shows a block diagram 200 of an apparatus 202 that supports a system to identify volatile organic compound biomarkers for disease detection and diagnosis in accordance with various aspects of the present disclosure. The apparatus 202 may be the same as, or similar to, one or more components described in connection with the device diagram 100 of FIG. 1. The apparatus 202 may include an input module 204, breath analysis component 206, and an output module 208. The apparatus 202 may also include a processor. Each of these components may be in communication with one another (e.g., via one or more buses). In some cases, the apparatus 202 may be an example of a user terminal, a database server, or a system containing multiple computing devices.
[0051] The input module 204 may manage input signals for the apparatus 202. For example, the input module 204 may identify input signals based on an interaction with a modem, a keyboard, a mouse, a touchscreen, or a similar device. These input signals may be associated with user input or processing at other components or devices. In some cases, the input module 204 may utilize an operating system such as iOS®, ANDROID®, MS-DOS®, MS-WINDOWS®, OS / 2®, UNIX®, LINUX®, or another known operating system to handle input signals. The input module 204 may send aspects of these input signals to other components of the apparatus 202 for processing. In some cases, the input module 204 may be a component of an input / output (I / O) controller 406 as described with reference to FIG. 4.
[0052] The breath analysis component 206 may include one or more of a data receiving component 210, an impedance analysis component 212, a pattern learning component 214, a biomarker association component 216, a condition recording component 218, and / or other components. The breath analysis component 206 may be an example of aspects of the breath analysis component 302 or 404 described with reference to FIGS. 3 and 4, respectively.12 #19302804vlAtty Docket: STR-028W001
[0053] The data receiving component 210 may be configured as or otherwise support a means for receiving exhaled breath sample data from a breath analysis device, the data including transduced impedance values generated by a plurality of sensing elements of an aroma chip. The impedance analysis component 212 may be configured as or otherwise support a means for analyzing the transduced impedance values in response to receiving the exhaled breath sample data to identify patterns indicative of volatile organic compound biomarkers. The pattern learning component 214 may be configured as or otherwise support a means for comparing the identified patterns with stored reference data associated with volatile organic compound biomarkers to determine the presence and concentration of the biomarkers. The biomarker association component 216 may be configured as or otherwise support a means for associating the determined biomarkers with stored disease profiles to identify potential health conditions. The condition recording component 218 may be configured as or otherwise support a means for recording the associated health conditions and determined biomarkers in a database.
[0054] The output module 208 may manage output signals for the apparatus 202. For example, the output module 208 may receive signals from other components of the apparatus 202, such as the breath analysis component 206, and may transmit these signals to other components or devices. In some specific examples, the output module 208 may transmit output signals for display in a user interface, for storage in a database or data store, for further processing at a server or server cluster, or for any other processes at any number of devices or systems. In some cases, the output module 208 may be a component of an I / O controller 406 as described with reference to FIG. 4.
[0055] FIG. 3 shows a block diagram 300 of a breath analysis component 302 that supports system to identify volatile organic compound biomarkers for disease detection and diagnosis in accordance with various aspects of the present disclosure. The breath analysis component 302 may be an example of aspects of a breath analysis component 206, a breath analysis component 404, or both, as described herein. The breath analysis component 302, or various components thereof, may be an example of means for performing various aspects of system to identify volatile organic compound biomarkers for disease detection and diagnosis as described herein. For example, the breath analysis component 302 may include one or more of a data receiving component 304, an impedance analysis component 306, a pattern learning component 308, a biomarker association component 310, a condition recording component 312, an environmental adjustment component 314, a breath portion identification component 316, a 13 #19302804vlAtty Docket: STR-028W001data filtering component 318, a breathprint generation component 320, a remote transmission component 322, and / or other components. Each of these components may communicate, directly or indirectly, with one another (e.g., via one or more buses).
[0056] The data receiving component 304 may be configured as or otherwise support a means for receiving exhaled breath sample data from a breath analysis device, the data may include transduced impedance values generated by a plurality of sensing elements of an aroma chip. The data receiving component 304 may include a wireless communication module to exchange data with a remote server hosting Al models. The data receiving component 304 may support wired communication interfaces, such as USB or Ethernet, for transferring data to external processing units. The data receiving component 304 may be integrated with a local processor to temporarily store transduced impedance values before transmitting them for further analysis.
[0057] The impedance analysis component 306 may be configured as or otherwise support a means for analyzing the transduced impedance values in response to receiving the exhaled breath sample data to identify patterns that may be indicative of volatile organic compound biomarkers. The impedance analysis component 306 may determine variations in electrical impedance across interdigitated electrodes embedded in the composite thin films of the aroma chip. In some implementations, the impedance analysis component 306 may analyze changes in impedance caused by the expansion or contraction of the composite thin films during interaction with volatile organic compound biomarkers. The impedance analysis component 306 may process impedance data to detect unique fingerprints associated with specific combinations of volatile organic compound biomarkers.
[0058] The pattern learning component 308 may be configured as or otherwise support a means for comparing the identified patterns with stored reference data that may be associated with volatile organic compound biomarkers to determine the presence and concentration of the biomarkers. The stored reference data may include fingerprints generated from prior breath samples collected in environments with varying humidity levels. In some implementations, the stored reference data may consist of fingerprints associated with specific disease conditions, where the fingerprints may represent unique combinations of volatile organic compound biomarkers. The pattern learning component 308 may determine the presence of biomarkers by matching impedance fingerprints with reference fingerprints stored in a database. In some implementations, the reference fingerprints may be categorized based on the concentration14 #19302804vlAtty Docket: STR-028W001ranges of volatile organic compound biomarkers relevant to different health conditions. The pattern learning component 308 may analyze the concentration of biomarkers by comparing the magnitude of impedance changes in the identified patterns with corresponding reference values.
[0059] The biomarker association component 310 may be configured as or otherwise support a means for associating the determined biomarkers with stored disease profiles to identify potential health conditions. In some implementations, the biomarker association component 310 may associate biomarkers with disease profiles based on unique combinations of volatile organic compound biomarkers detected in the exhaled breath sample. The biomarker association component 310 may determine associations by referencing stored disease profiles that include specific concentration ranges of volatile organic compound biomarkers relevant to various health conditions. In some implementations, the biomarker association component 310 may utilize disease profiles that are categorized based on environmental conditions, such as varying humidity levels, to account for potential variations in biomarker concentrations. The biomarker association component 310 may determine associations by comparing the identified biomarkers with disease profiles that include reference data collected from breath samples in controlled environments.
[0060] The condition recording component 312 may be configured as or otherwise support a means for recording the associated health conditions and determined biomarkers in a database. In some implementations, the condition recording component 312 may store data related to the concentration ranges of volatile organic compound biomarkers detected in exhaled breath samples. The condition recording component 312 may record environmental parameters, such as humidity levels and / or temperature conditions, which may influence the concentration of biomarkers. In some implementations, the condition recording component 312 may categorize recorded health conditions based on unique combinations of biomarkers identified during breath sample analysis. The condition recording component 312 may include timestamp functionality to record the time and date of each health condition and biomarker determination.
[0061] In some examples, the environmental adjustment component 314 may be configured as or otherwise support a means for receiving environmental data from sensors associated with the breath analysis device, the data including temperature, pressure, and / or humidity conditions, and adjusting the analysis of the transduced impedance values to account15 #19302804vlAtty Docket: STR-028W001for variations in the environmental data. In some implementations, the environmental adjustment component 314 may receive data from temperature sensors placed near the aroma chip enclosure to determine the ambient temperature during breath sample analysis. In some implementations, the environmental adjustment component 314 may receive pressure data from barometric sensors integrated into the breath analysis device to determine variations in atmospheric pressure that may influence impedance values. In some implementations, the environmental adjustment component 314 may receive humidity data from sensors positioned near the buffer chamber to determine the absolute humidity levels of the operating environment.
[0062] In some examples, the environmental adjustment component 314 may adjust the analysis of the transduced impedance values to account for variations in the environmental data. In some implementations, the environmental adjustment component 314 may adjust impedance analysis by referencing stored environmental profiles that include baseline impedance values for varying temperature conditions. In some implementations, the environmental adjustment component 314 may adjust impedance analysis by determining the impact of pressure variations on the contraction or expansion of composite thin films in the aroma chip. In some implementations, the environmental adjustment component 314 may adjust impedance analysis by determining the influence of humidity levels on the interaction between volatile organic compound biomarkers and the sensing elements of the aroma chip.
[0063] In some examples, the breath portion identification component 316 may be configured as or otherwise support a means for identifying exhaled breath sample portions based on carbon dioxide levels detected by a capnography unit, and segregating alveolar portions of the breath sample for analysis of volatile organic compound biomarkers. In some implementations, the breath portion identification component 316 may determine the alveolar portion by analyzing the peak carbon dioxide levels during the exhalation phase. In some implementations, the breath portion identification component 316 may include sensors to detect flow rate variations that may correspond to the transition between alveolar and non-alveolar portions of the breath sample. In some implementations, the breath portion identification component 316 may adjust the timing of sample segregation based on real-time carbon dioxide concentration data received from the capnography unit.
[0064] In some examples, the data filtering component 318 may be configured as or otherwise support a means for filtering exhaled breath sample data to remove impedance values16 #19302804vlAtty Docket: STR-028W001that may be associated with non-relevant volatile organic compounds, based on stored reference data for compounds that may be unrelated to disease detection. In some implementations, the data filtering component 318 may filter impedance values associated with volatile organic compounds that may originate from environmental contaminants, such as cleaning agents or perfumes. In some implementations, the data filtering component 318 may determine non-relevant impedance values by referencing stored data profiles that may include baseline measurements from controlled environments. In some implementations, the data filtering component 318 may exclude impedance values associated with volatile organic compounds that may be present in exhaled breath samples due to dietary intake, such as compounds from garlic or coffee.
[0065] In some examples, the breathprint generation component 320 may be configured as or otherwise support a means for generating a breathprint from the transduced impedance values, the breathprint may represent a combination of volatile organic compound biomarkers, and may correlate the breathprint with stored disease profiles to refine identification of health conditions. In some implementations, the breathprint generation component 320 may determine unique impedance patterns by analyzing the interaction of volatile organic compound biomarkers with the composite thin films of the aroma chip. In some implementations, the breathprint generation component 320 may generate breathprints that may reflect variations in impedance caused by environmental factors, such as humidity or temperature, during breath sample analysis. In some implementations, the breathprint generation component 320 may determine breathprints that may include impedance values associated with specific functional groups of volatile organic compound biomarkers detected in the exhaled breath sample.
[0066] In some examples, the remote transmission component 322 may be configured as or otherwise support a means for transmitting the associated health conditions and determined biomarkers to a remote server for storage, and may enable access to the stored data for subsequent disease screening and diagnostic applications. In some implementations, the remote transmission component 322 may transmit data through a wireless communication module that may support protocols such as Wi-Fi or Bluetooth. In some implementations, the remote transmission component 322 may include a wired communication interface, such as Ethernet or USB, to transfer data to external servers or processing units. In some implementations, the remote transmission component 322 may temporarily store the transmitted data locally before sending it to the remote server to account for potential network delays.17 #19302804vlAtty Docket: STR-028W001
[0067] FIG. 4 shows a diagram of a system 400 including a device 402 that supports system to identify volatile organic compound biomarkers for disease detection and diagnosis in accordance with aspects of the present disclosure. The device 402 may be an example of or include the components of a database server or an apparatus 202 as described herein. The device 402 may include components for bi-directional data communications including components for transmitting and receiving communications, including a breath analysis component 404, an I / O controller 406, a database controller 408, memory 410, a processor 412, and a database 414. These components may be in electronic communication via one or more buses (e.g., bus 416).
[0068] The breath analysis component 404 may be an example of a breath analysis component 206 or 302 as described herein. For example, the breath analysis component 404 may perform any of the methods or processes described above with reference to FIGS. 2 and 3. In some cases, the breath analysis component 404 may be implemented in hardware, software executed by a processor, firmware, or any combination thereof.
[0069] The I / O controller 406 may manage input signals 418 and output signals 420 for the device 402. The I / O controller 406 may also manage peripherals not integrated into the device 402. In some cases, the VO controller 406 may represent a physical connection or port to an external peripheral. In some cases, the I / O controller 406 may utilize an operating system such as iOS®, ANDROID®, MS-DOS®, MS-WINDOWS®, OS / 2®, UNIX®, LINUX®, or another known operating system. In other cases, the I / O controller 406 may represent or interact with a modem, a keyboard, a mouse, a touchscreen, or a similar device. In some cases, the I / O controller 406 may be implemented as part of a processor. In some cases, a user may interact with the device 402 via the I / O controller 406 or via hardware components controlled by the I / O controller 406.
[0070] The database controller 408 may manage data storage and processing in a database 414. In some cases, a user may interact with the database controller 408. In other cases, the database controller 408 may operate automatically without user interaction. The database 414 may be an example of a single database, a distributed database, multiple distributed databases, a data store, a data lake, or an emergency backup database.
[0071] Memory 410 may include random-access memory (RAM) and read-only memory (ROM). The memory 410 may store computer-readable, computer-executable software including instructions that, when executed, cause the processor to perform various functions18 #19302804vlAtty Docket: STR-028W001described herein. In some cases, the memory 410 may contain, among other things, a basic input / output system (BIOS) which may control basic hardware or software operation such as the interaction with peripheral components or devices.
[0072] The processor 412 may include an intelligent hardware device, (e.g., a general-purpose processor, a DSP, a central processing unit (CPU), a microcontroller, an ASIC, an FPGA, a programmable logic device, a discrete gate or transistor logic component, a discrete hardware component, or any combination thereof). In some cases, the processor 412 may be configured to operate a memory array using a memory controller. In other cases, a memory controller may be integrated into the processor 412. The processor 412 may be configured to execute computer-readable instructions stored in a memory 410 to perform various functions (e.g., functions or tasks supporting system to identify volatile organic compound biomarkers for disease detection and diagnosis).
[0073] FIG. 5 shows a flowchart illustrating a method 500 that supports a system to identify volatile organic compound biomarkers for disease detection and diagnosis in accordance with various aspects of the present disclosure. The operations of the methods described herein may be implemented by one or more of a device, an apparatus, a system (e.g., a networked computing system), and / or components thereof as described herein. For example, the operations of the method 500 may be performed by a breath analysis component as described with reference to any of FIGS. 2-4. In some examples, one or more components of a device, apparatus, and / or system may execute a set of instructions to control the functional elements of the component(s) to perform the described functions. Additionally or alternatively, the one or more components of a device, apparatus, and / or system may perform aspects of the described functions using special-purpose hardware.
[0074] At 502, the method 500 may include receiving exhaled breath sample data from a breath analysis device, the data including transduced impedance values generated by a plurality of sensing elements of an aroma chip. The operations of 502 may be performed in accordance with examples as disclosed herein. In some examples, aspects of the operations of 502 may be performed by a data receiving component 304 as described with reference to FIG. 3.
[0075] At 504, the method 500 may include analyzing the transduced impedance values in response to receiving the exhaled breath sample data to identify patterns indicative of volatile organic compound biomarkers. The operations of 504 may be performed in accordance with19 #19302804vlAtty Docket: STR-028W001examples as disclosed herein. In some examples, aspects of the operations of 504 may be performed by an impedance analysis component 306 as described with reference to FIG. 3.
[0076] At 506, the method 500 may include comparing the identified patterns with stored reference data associated with volatile organic compound biomarkers to determine the presence and concentration of the biomarkers. The operations of 506 may be performed in accordance with examples as disclosed herein. In some examples, aspects of the operations of 506 may be performed by a pattern learning component 308 as described with reference to FIG. 3.
[0077] At 508, the method 500 may include associating the determined biomarkers with stored disease profiles to identify potential health conditions. The operations of 508 may be performed in accordance with examples as disclosed herein. In some examples, aspects of the operations of 508 may be performed by a biomarker association component 310 as described with reference to FIG. 3.
[0078] At 510, the method 500 may include recording the associated health conditions and determined biomarkers in a database. The operations of 510 may be performed in accordance with examples as disclosed herein. In some examples, aspects of the operations of 510 may be performed by a condition recording component 312 as described with reference to FIG. 3.
[0079] FIG. 6 shows a flowchart illustrating a method 600 involving breath analysis devices in accordance with various aspects of the present disclosure.
[0080] At 602, the method 600 may include providing an aroma chip with composite thin-film sensing elements, each functionalized with a polymer and conducting nanoparticles. The operations of 602 may be performed in accordance with examples as disclosed herein. In some examples, aspects of the operations of 602 may involve aroma chip 108 as described with reference to FIG. 1.
[0081] At 604, the method 600 may include assembling a sample collection pathway including a mouthpiece, a buffer chamber, and valves configured to control the introduction of exhaled breath samples to the aroma chip. The operations of 604 may be performed in accordance with examples as disclosed herein. In some examples, aspects of the operations of 604 may involve exhaled breath capturing module / buffer chamber 102 as described with reference to FIG. 1.
[0082] At 606, the method 600 may include integrating a plurality of conditioning modules configured to modulate environmental factors affecting the aroma chip, including humidity and20 #19302804vlAtty Docket: STR-028W001temperature. The operations of 606 may be performed in accordance with examples as disclosed herein. In some examples, aspects of the operations of 606 may involve the first conditioning module 104 and second conditioning module 106 as described with reference to FIG. 1.
[0083] At 608, the method 600 may include incorporating a processor configured to analyze electrical responses from the aroma chip in response to exhaled breath samples. The operations of 608 may be performed in accordance with examples as disclosed herein. In some examples, aspects of the operations of 608 may involve aroma chip 108 as described with reference to FIG. 1.
[0084] At 610, the method 600 may include installing a communication module configured to transmit data between the processor and a remote server. The operations of 610 may be performed in accordance with examples as disclosed herein. In some examples, aspects of the operations of 610 may involve aroma chip 108 as described with reference to FIG. 1.
[0085] FIG. 7 illustrates a schematic view of a breath analysis device 700 (e.g., the DiagNoze system developed by Noze, Inc. Montreal, Canada) according to an embodiment of the present invention, specifically highlighting the fluidic pathway and sample conditioning assembly. The device 700 includes an intake assembly comprising a mouthpiece 701 configured to receive a breath sample from a user. Within or immediately downstream of the mouthpiece is a check valve 702 (e.g., a duckbill or one-way valve) designed to ensure unidirectional flow and prevent backflow or contamination. The breath sample then passes through an integrated humidity and microbial filter 703, which serves as a biological barrier to protect the internal fluidic components from pathogens, at the same time filtering out the humidity. Downstream of the integrated microbial filter 703, the device includes a first multiway valve 704 (e.g., a capnography valve). In a first state, the valve 704 is configured to divert the initial "dead space" or exogenous breath through an exogenous exhaust port 705. Upon detection of a specific physiological trigger — such as a threshold carbon dioxide concentration detected by an integrated capnography sensor — the valve 704 switches to a second state to divert the alveolar (deep-lung) breath into a buffer chamber 706. The buffer chamber 706 is configured to store a fixed volume of the alveolar breath sample to ensure a controlled and stabilized delivery to the sensing assembly. The fluidic path downstream of the buffer chamber 706 includes a secondary exhaust / relief valve 707 to manage internal pressure and flow. The delivery of the sample is controlled by a second multi-way valve 708 (e.g., a flow diversion).21 #19302804vlAtty Docket: STR-028W001This valve 708 selectively couples the sensing assembly to either the buffer chamber 706 (during a sensing cycle) or a baseline air intake 710 (during a recovery or calibration cycle). The baseline air intake 710 is fluidly coupled to a relative humidity (RH) filter or desiccant bed 711 to provide conditioned ambient air for purging the sensors. The sensing assembly comprises an aroma sensor chip 709 (the "Noze" sensor or the aroma chip) positioned within a sensor housing. As the breath sample or baseline air is drawn across the sensor chip 709 — facilitated by a downstream pump (not shown) — the sensing elements on the chip 709 generate transduced signals (e.g., impedance changes) based on the presence of specific volatile organic compound (VOC) biomarkers. These signals are subsequently processed to provide a diagnostic output as described in the general specification.
[0086] It should be noted that the methods described herein describe possible implementations, and that the operations and the steps may be rearranged or otherwise modified and that other implementations are possible. Furthermore, aspects from two or more of the methods may be combined.
[0087] Aspect 1: A digital olfaction-based breath analysis device, comprising: an aroma chip including composite thin-film sensing elements, each functionalized with a polymer and conducting nanoparticles; a sample collection pathway including a mouthpiece, a buffer chamber, and valves configured to control the introduction of exhaled breath samples to the aroma chip; a plurality of conditioning modules configured to modulate environmental factors affecting the aroma chip, including humidity and temperature; a processor configured to analyze electrical responses from the aroma chip in response to exhaled breath samples; and a communication module configured to transmit data between the processor and a remote server.
[0088] Aspect 2: The digital olfaction-based breath analysis device of aspect 1, further comprising a conditioning module positioned within the buffer chamber, the conditioning module configured to selectively capture exhaled breath condensate and release the condensate to the aroma chip in response to temperature modulation.
[0089] Aspect 3: The digital olfaction-based breath analysis device of any of aspects 1 through 2, wherein the valves of the sample collection pathway include a valve between the mouthpiece and the buffer chamber, the valve configured to segregate relevant portions of exhaled breath samples based on input from a CO2 sensor.
[0090] Aspect 4: The digital olfaction-based breath analysis device of any of aspects 1 through 3, further comprising an exhaled breath capturing module located adjacent to the 22 #19302804vlAtty Docket: STR-028W001mouthpiece, the exhaled breath capturing module configured to condition exhaled breath samples by filtering humidity prior to introduction into the buffer chamber.
[0091] Aspect 5: The digital olfaction-based breath analysis device of any of aspects 1 through 4, wherein the aroma chip includes sensing elements functionalized with polymers selected for semi-selective interaction with functional groups of volatile organic compounds in exhaled breath samples.
[0092] Aspect 6: The digital olfaction-based breath analysis device of any of aspects 1 through 5, further comprising a conditioning module positioned near the aroma chip, the conditioning module configured to modulate the temperature of environment air introduced during baseline and recovery phases.
[0093] Aspect 7: The digital olfaction-based breath analysis device of any of aspects 1 through 6, wherein the buffer chamber includes a configurable volume that is adjustable between 150 cc and 500 cc in response to the disease condition targeted by the device.
[0094] Aspect 8: The digital olfaction-based breath analysis device of any of aspects 1 through 7, wherein the aroma chip includes sensing elements functionalized with polymers selected to interact with volatile organic compounds dissolved in exhaled breath condensate.
[0095] Aspect 9: The digital olfaction-based breath analysis device of any of aspects 1 through 8, wherein the conditioning module includes a humidity filter comprising desiccant material and filtering media configured to remove water content from exhaled breath samples.
[0096] Aspect 10: The digital olfaction-based breath analysis device of any of aspects 1 through 9, wherein the exhaled breath capturing module includes a bacterial viral filter configured to prevent introduction of bacteria or viruses into the buffer chamber.
[0097] Aspect 11: The digital olfaction-based breath analysis device of any of aspects 1 through 10, wherein the aroma chip includes sensing elements functionalized with polymers selected to produce unique electrical responses based on the presence and concentration of volatile organic compounds.
[0098] Aspect 12: The digital olfaction-based breath analysis device of any of aspects 1 through 11, wherein the conditioning module includes a temperature control module configured to modulate the temperature of exhaled breath samples prior to introduction into the buffer chamber.23 #19302804vlAtty Docket: STR-028W001
[0099] Aspect 13: The digital olfaction-based breath analysis device of any of aspects 1 through 12, wherein the environment air introduced during the baseline phase is conditioned by the conditioning module to remove humidity prior to interaction with the aroma chip.
[0100] Aspect 14: A method of forming a digital olfaction-based breath analysis device, comprising: providing an aroma chip with composite thin-film sensing elements, each functionalized with a polymer and conducting nanoparticles; assembling a sample collection pathway including a mouthpiece, a buffer chamber, and valves configured to control the introduction of exhaled breath samples to the aroma chip; integrating a plurality of conditioning modules configured to modulate environmental factors affecting the aroma chip, including humidity and temperature; incorporating a processor configured to analyze electrical responses from the aroma chip in response to exhaled breath samples; and installing a communication module configured to transmit data between the processor and a remote server.
[0101] Aspect 15 : A method for a system to identify volatile organic compound biomarkers for disease detection and diagnosis, comprising: receiving exhaled breath sample data from a breath analysis device, the data including transduced impedance values generated by a plurality of sensing elements of an aroma chip; analyzing the transduced impedance values in response to receiving the exhaled breath sample data to identify patterns indicative of volatile organic compound biomarkers; comparing the identified patterns with stored reference data associated with volatile organic compound biomarkers to determine the presence and concentration of the biomarkers; associating the determined biomarkers with stored disease profiles to identify potential health conditions; and recording the associated health conditions and determined biomarkers in a database.
[0102] Aspect 16: The method of aspect 15, further comprising: receiving environmental data from sensors associated with the breath analysis device, the data including temperature, pressure, and humidity conditions, and adjusting the analysis of the transduced impedance values to account for variations in the environmental data.
[0103] Aspect 17: The method of any of aspects 15 through 16, further comprising: identifying exhaled breath sample portions based on carbon dioxide levels detected by a capnography unit, and segregating alveolar portions of the breath sample for analysis of volatile organic compound biomarkers.
[0104] Aspect 18: The method of any of aspects 15 through 17, further comprising: filtering exhaled breath sample data to remove impedance values associated with non-relevant 24 #19302804vlAtty Docket: STR-028W001volatile organic compounds, based on stored reference data for compounds unrelated to disease detection.
[0105] Aspect 19: The method of any of aspects 15 through 18, further comprising: generating a unique breathprint from the transduced impedance values, the breathprint representing a combination of volatile organic compound biomarkers, and correlating the breathprint with stored disease profiles to refine identification of health conditions.
[0106] Aspect 20: The method of any of aspects 15 through 19, further comprising: transmitting the associated health conditions and determined biomarkers to a remote server for storage, and enabling access to the stored data for subsequent disease screening and diagnostic applications.
[0107] Aspect 21: The method of any of aspects 15 through 20, wherein the transduced impedance values are analyzed in response to detecting a specific combination of volatile organic compound biomarkers indicative of respiratory diseases, metabolic disorders, or infectious conditions.
[0108] Aspect 22: The method of any of aspects 15 through 21, wherein the stored reference data includes volatile organic compound biomarkers associated with gastrointestinal diseases, neurological disorders, or cardiovascular conditions.
[0109] Aspect 23 : The method of any of aspects 15 through 22, wherein the exhaled breath sample data is processed to identify volatile organic compound biomarkers indicative of disease progression, remission, or recurrence.
[0110] Aspect 24: The method of any of aspects 15 through 23, wherein the database includes historical data correlating volatile organic compound biomarkers with patient demographics, lifestyle factors, or environmental exposures.
[0111] Aspect 25: A system for identifying volatile organic compound biomarkers for disease detection and diagnosis, comprising a processor; memory coupled with the processor; and instructions stored in the memory and executable by the processor to cause the system to perform a method of any of aspects 15 through 24.
[0112] Aspect 26: A system for identifying volatile organic compound biomarkers for disease detection and diagnosis, comprising at least one means for performing a method of any of aspects 15 through 24.25 #19302804vlAtty Docket: STR-028W001
[0113] Aspect 27: A non-transitory computer-readable medium storing code for identifying volatile organic compound biomarkers for disease detection and diagnosis, the code comprising instructions executable by a processor to perform a method of any of aspects 15 through 24.
[0114] The description set forth herein, in connection with the appended drawings, describes example configurations and does not represent all the examples that may be implemented or that are within the scope of the claims. The term “exemplary” used herein means “serving as an example, instance, or illustration,” and not “preferred” or “advantageous over other examples.” The detailed description includes specific details for the purpose of providing an understanding of the described techniques. These techniques, however, may be practiced without these specific details. In some instances, well-known structures and devices are shown in block diagram form in order to avoid obscuring the concepts of the described examples.
[0115] In the appended figures, similar components or features may have the same reference label. Further, various components of the same type may be distinguished by following the reference label by a dash and a second label that distinguishes among the similar components. If just the first reference label is used in the specification, the description is applicable to any one of the similar components having the same first reference label irrespective of the second reference label.
[0116] Information and signals described herein may be represented using any of a variety of different technologies and techniques. For example, data, instructions, commands, information, signals, bits, symbols, and chips that may be referenced throughout the above description may be represented by voltages, currents, electromagnetic waves, magnetic fields or particles, optical fields or particles, or any combination thereof.
[0117] The various illustrative blocks and modules described in connection with the disclosure herein may be implemented or performed with a general-purpose processor, a DSP, an ASIC, an FPGA or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or any combination thereof designed to perform the functions described herein. A general-purpose processor may be a microprocessor, but in the alternative, the processor may be any conventional processor, controller, microcontroller, or state machine. A processor may also be implemented as a combination of computing devices (e.g., a26 #19302804vlAtty Docket: STR-028W001combination of a DSP and a microprocessor, multiple microprocessors, one or more microprocessors in conjunction with a DSP core, or any other such configuration).
[0118] The functions described herein may be implemented in hardware, software executed by a processor, firmware, or any combination thereof. If implemented in software executed by a processor, the functions may be stored on or transmitted over as one or more instructions or code on a computer-readable medium. Other examples and implementations are within the scope of the disclosure and appended claims. For example, due to the nature of software, functions described herein can be implemented using software executed by a processor, hardware, firmware, hardwiring, or combinations of any of these. Features implementing functions may also be physically located at various positions, including being distributed such that portions of functions are implemented at different physical locations. Also, as used herein, including in the claims, “or” as used in a list of items (for example, a list of items prefaced by a phrase such as “at least one of’ or “one or more of’) indicates an inclusive list such that, for example, a list of at least one of A, B, or C means A or B or C or AB or AC or BC or ABC (i.e., A and B and C). Also, as used herein, the phrase “based on” shall not be construed as a reference to a closed set of conditions. For example, an exemplary step that is described as “based on condition A” may be based on both a condition A and a condition B without departing from the scope of the present disclosure. In other words, as used herein, the phrase “based on” shall be construed in the same manner as the phrase “based at least in part on.”
[0119] Computer-readable media includes both non-transitory computer storage media and communication media including any medium that facilitates transfer of a computer program from one place to another. A non-transitory storage medium may be any available medium that can be accessed by a general purpose or special purpose computer. By way of example, and not limitation, non-transitory computer-readable media can comprise RAM, ROM, electrically erasable programmable read only memory (EEPROM), compact disk (CD) ROM or other optical disk storage, magnetic disk storage or other magnetic storage devices, or any other non-transitory medium that can be used to carry or store desired program code means in the form of instructions or data structures and that can be accessed by a general-purpose or specialpurpose computer, or a general-purpose or special-purpose processor. Also, any connection is properly termed a computer-readable medium. For example, if the software is transmitted from a website, server, or other remote source using a coaxial cable, fiber optic cable, twisted pair, digital subscriber line (DSL), or wireless technologies such as infrared, radio, and microwave, then the coaxial cable, fiber optic cable, twisted pair, DSL, or wireless technologies such as 27 #19302804vlAtty Docket: STR-028W001infrared, radio, and microwave are included in the definition of medium. Disk and disc, as used herein, include CD, laser disc, optical disc, digital versatile disc (DVD), floppy disk and Blu-ray disc where disks usually reproduce data magnetically, while discs reproduce data optically with lasers. Combinations of the above are also included within the scope of computer-readable media.
[0120] The description herein is provided to enable a person skilled in the art to make or use the disclosure. Various modifications to the disclosure will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other variations without departing from the scope of the disclosure. Thus, the disclosure is not limited to the examples and designs described herein, but is to be accorded the broadest scope consistent with the principles and novel features disclosed herein.28 #19302804vl
Claims
Atty Docket: STR-028W001CLAIMS1. A digital olfaction-based breath analysis device, comprising:an aroma chip including composite thin-film sensing elements, each functionalized with a polymer and conducting nanoparticles;a sample collection pathway including a mouthpiece, a buffer chamber, and valves configured to control introduction of exhaled breath samples to the aroma chip;a plurality of conditioning modules configured to modulate environmental factors affecting the aroma chip, including humidity and temperature;a processor configured to analyze electrical responses from the aroma chip in response to exhaled breath samples; anda communication module configured to transmit data between the processor and a remote server.
2. The digital olfaction-based breath analysis device of claim 1, further comprising a conditioning module positioned within the buffer chamber, the conditioning module configured to selectively capture exhaled breath condensate and release the condensate to the aroma chip in response to temperature modulation.
3. The digital olfaction-based breath analysis device of claim 1, wherein the valves of the sample collection pathway include a valve between the mouthpiece and the buffer chamber, the valve configured to segregate relevant portions of exhaled breath samples based on input from a CO2 sensor.
4. The digital olfaction-based breath analysis device of claim 1, further comprising an exhaled breath capturing module located adjacent to the mouthpiece, the exhaled breath capturing module configured to condition exhaled breath samples by filtering humidity prior to introduction into the buffer chamber.
5. The digital olfaction-based breath analysis device of claim 4, wherein the exhaled breath capturing module includes a bacterial viral filter configured to prevent introduction of bacteria or viruses into the buffer chamber.29 #19302804vlAtty Docket: STR-028W0016. The digital olfaction-based breath analysis device of claim 1, wherein the aroma chip includes sensing elements functionalized with polymers selected for semi-selective interaction with functional groups of volatile organic compounds in exhaled breath samples.
7. The digital olfaction-based breath analysis device of claim 1, further comprising a conditioning module positioned near the aroma chip, the conditioning module configured to modulate the temperature of environment air introduced during baseline and recovery phases.
8. The digital olfaction-based breath analysis device of claim 1, wherein the buffer chamber includes a configurable volume that is adjustable between 150 cc and 500 cc in response to a disease condition targeted by the device.
9. The digital olfaction-based breath analysis device of claim 1, wherein the aroma chip includes sensing elements functionalized with polymers selected to interact with volatile organic compounds dissolved in exhaled breath condensate.
10. The digital olfaction-based breath analysis device of claim 1, wherein the plurality of conditioning modules includes a humidity filter comprising desiccant material and filtering media configured to remove water content from exhaled breath samples.
11. The digital olfaction-based breath analysis device of claim 1, wherein the aroma chip includes sensing elements functionalized with polymers selected to produce unique electrical responses based on a presence and concentration of volatile organic compounds.
12. The digital olfaction-based breath analysis device of claim 1, wherein the plurality of conditioning modules includes a temperature control module configured to modulate the temperature of exhaled breath samples prior to introduction into the buffer chamber.
13. The digital olfaction-based breath analysis device of claim 1, wherein environment air introduced during a baseline phase is conditioned by the plurality of conditioning modules to remove humidity prior to interaction with the aroma chip.
14. A method for system to identify volatile organic compound biomarkers for disease detection and diagnosis, comprising:30 #19302804vlAtty Docket: STR-028W001receiving an exhaled breath sample data from a breath analysis device, the data including transduced impedance values generated by a plurality of sensing elements of an aroma chip;analyzing the transduced impedance values in response to receiving the exhaled breath sample data to identify patterns indicative of volatile organic compound biomarkers;comparing the identified patterns with stored reference data associated with volatile organic compound biomarkers to determine a presence and concentration of the volatile organic compound biomarkers;associating the volatile organic compound biomarkers with stored disease profiles to identify potential health conditions; andrecording the associated potential health conditions and volatile organic compound biomarkers in a database.
15. The method of claim 14, further comprising receiving environmental data from sensors associated with the breath analysis device, the environmental data including temperature, pressure, and humidity conditions, and adjusting the analysis of the transduced impedance values to account for variations in the environmental data.
16. The method of claim 14, further comprising identifying exhaled breath sample portions based on carbon dioxide levels detected by a capnography unit, and segregating alveolar portions of the exhaled breath sample for analysis of volatile organic compound biomarkers.
17. The method of claim 14, further comprising filtering exhaled breath sample data to remove impedance values associated with non-relevant volatile organic compounds, based on stored reference data for compounds unrelated to disease detection.
18. The method of claim 14, further comprising generating a unique breathprint from the transduced impedance values, the breathprint representing a combination of volatile organic compound biomarkers, and correlating the breathprint with stored disease profiles to refine identification of health conditions.31 #19302804vlAtty Docket: STR-028W00119. The method of claim 14, further comprising transmitting the associated health conditions and determined biomarkers to a remote server for storage, and enabling access to the stored data for subsequent disease screening and diagnostic applications.
20. A system configured for identifying volatile organic compound biomarkers for disease detection and diagnosis, comprising:a processor;memory coupled with the processor; andinstructions stored in the memory and executable by the processor to cause the system to:receive exhaled breath sample data from a breath analysis device, the data including transduced impedance values generated by a plurality of sensing elements of an aroma chip;analyze the transduced impedance values in response to receiving the exhaled breath sample data to identify patterns indicative of volatile organic compound biomarkers;compare the identified patterns with stored reference data associated with volatile organic compound biomarkers to determine a presence and concentration of the biomarkers;associate the volatile organic compound biomarkers with stored disease profiles to identify potential health conditions; andrecord the associated health conditions and volatile organic compound biomarkers in a database.32 #19302804vl
